Can-Fite Biopharma (CANF) vs Pulmatrix (PULM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Can-Fite Biopharma is the larger company by market cap ($6.1 million vs $5.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CANF | PULM |
|---|---|---|
| Share price | $2.00 | $1.53 |
| Market cap | $6.06M | $5.58M |
| 1-day change | -4.76% | +2.49% |
| YTD return | -50.00% | — |
| 1-year return | -83.05% | — |
| 5-year return | -99.35% | — |
| EPS (TTM) | $-13.23 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.40 | $5.24 |
| 52-week low | $1.96 | $1.16 |
| Distance from 52-week high | -83.87% | -70.83% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +300.00% | — |
| Average volume | 388.00K | 24.09K |
| Shares outstanding | 3.03M | 3.65M |
| Employees | 5 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Can-Fite Biopharma
CANF stock →Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
Healthcare · Biotechnology · 5 employees
About Pulmatrix
PULM stock →Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Healthcare · Biotechnology · 2 employees
CANF vs PULM FAQ
Which is bigger, Can-Fite Biopharma or Pulmatrix?
Can-Fite Biopharma (CANF) is larger, with a market capitalization of $6.06M compared with $5.58M for Pulmatrix (PULM).
Are Can-Fite Biopharma and Pulmatrix in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.